8-K: Dexcom Exceeds 2025 Revenue Guidance, Forecasts Strong 2026

Dexcom reported preliminary unaudited Q4 and full-year 2025 revenue exceeding guidance, alongside a positive initial financial outlook for 2026 and a new CEO.

Summary

• Preliminary Q4 2025 total revenue reached approximately $1.260 billion, a 13% increase over Q4 2024.
• U.S. revenue for Q4 2025 was approximately $892 million (11% growth), while international revenue was approximately $368 million (18% growth).
• Preliminary fiscal year 2025 total revenue was approximately $4.662 billion, marking a 16% increase over 2024.
• The company reiterated its 2025 non-GAAP gross profit margin guidance of approximately 61% and non-GAAP operating margin guidance of 20-21%.
• For fiscal year 2026, Dexcom anticipates total revenue between $5.16 billion and $5.25 billion, representing 11-13% growth over 2025.
• 2026 non-GAAP gross profit margin is estimated at 63-64%, and non-GAAP operating margin at 22-23%.
• Jake Leach assumed the role of President and CEO on January 1, 2026, succeeding Kevin Sayer.
• Strategic initiatives for 2026 include a reimagined Stelo app with AI-enabled features, increased availability of the Dexcom G7 15 Day CGM System in pharmacies, and expanded global coverage for glucose biosensing technology.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary financial results exceeding guidance, provides a positive outlook for the upcoming fiscal year with growth and margin expansion, and announces a smooth CEO transition with a clear vision for continued innovation and market expansion. These factors collectively indicate a very positive sentiment.

Positives

• Preliminary Q4 2025 total revenue of $1.260 billion exceeded the high end of previous guidance.
• Fiscal year 2025 total revenue of $4.662 billion represents strong 16% growth over 2024, exceeding previous guidance.
• International revenue growth of 18% in Q4 2025 indicates strong global expansion.
• Initial launch of the G7 15 Day system is a positive product development.
• Positive 2026 outlook with projected revenue growth of 11-13% and improved non-GAAP margins (63-64% gross, 22-23% operating).
• Continued innovation with a reimagined Stelo app, AI-enabled features, and increased product availability.
• Expanded coverage for glucose biosensing technology for millions globally.

Risks

• Actual results could differ materially from forward-looking statements due to various risks and uncertainties.
• Risks and uncertainties are more fully described in the sections titled Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations in Dexcom's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings.

Future Outlook

Dexcom anticipates continued strong growth in 2026, projecting total revenue between $5.16 billion and $5.25 billion, an 11-13% increase over 2025. This growth is expected to be driven by increased CGM awareness, the ongoing rollout of Stelo, further international expansion, and overall market dynamics. The company also forecasts improved non-GAAP gross profit margins of 63-64% and non-GAAP operating margins of 22-23% for 2026. Strategic initiatives include a reimagined Stelo app with AI-enabled features, increased availability of the Dexcom G7 15 Day CGM System in pharmacies, and expanded global coverage for glucose biosensing technology.

Management Comments

• "We are pleased to finish 2025 on a strong note with revenue exceeding the high end of our guidance and the initial launch of our latest sensor technology with the G7 15 Day system." Jake Leach, President and CEO.
• "With clinical momentum building across the CGM category, we look forward to extending our growth runway through continued innovation and evidence generation in 2026." Jake Leach, President and CEO.
• "I've had the honor of playing a role in shaping Dexcom's industry-defining innovation since joining the company more than 20 years ago. From building the technology as an engineer in my early days, to advancing global scale to meet our long-term growth demand as COO, its an honor to step into the role of CEO during such a pivotal moment for the business—and a growing global metabolic health crisis." Jake Leach, President and CEO.
• "I look forward to further advancing Dexcom's long legacy of empowering people to take control of health." Jake Leach, President and CEO.

Industry Context

The announcement highlights Dexcom's continued leadership in the rapidly expanding continuous glucose monitoring (CGM) market, driven by increasing awareness for diabetes management and the broader 'global metabolic health crisis.' The focus on AI-enabled features, personalized insights, and integrations with other health tech (like Oura Ring) aligns with the broader industry trend towards comprehensive, user-centric digital health solutions. The expansion of product availability and coverage reflects the growing demand and adoption of CGM technology beyond traditional insulin-dependent diabetes.

Comparison to Industry Standards

• Dexcom's revenue growth and market leadership in glucose biosensing for over 25 years set a high standard in the CGM category.
• The company's ability to exceed its own revenue guidance for 2025 suggests strong execution relative to internal benchmarks and potentially outperforming some competitors in market penetration or product adoption.
• The continued rollout of Stelo and the G7 15 Day system, along with integrations with platforms like Insulet's Omnipod 5 and Oura Ring, demonstrate a commitment to innovation and ecosystem development that is competitive within the medical device and digital health sectors.
• The projected non-GAAP operating margin of 22-23% for 2026 indicates a healthy profitability outlook, which is generally favorable compared to many growth-oriented medical technology companies.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance exceeding guidance, positive 2026 outlook, and continued innovation, potentially leading to increased share value.
• Customers (People with Diabetes): Positive impact from increased product availability (G7 15 Day in pharmacies), expanded coverage, and enhanced user experiences through the reimagined Stelo app and AI-enabled features.
• Employees: Potential positive impact from continued company growth and innovation, suggesting stability and opportunities.
• Healthcare System/Clinicians: Positive impact from advanced continuous health monitoring technology and expanded access, aiding in better patient management.

Next Steps

• Jake Leach to deliver opening presentation at the J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026, outlining his vision and key milestones for 2026.
• Dexcom will report its audited full fourth quarter and fiscal 2025 financial results on Thursday, February 12, 2026, after the close of market.
• Management is scheduled to host a conference call on February 12, 2026, at 4:30 p.m. (Eastern Time) to discuss audited results.
• Continued rollout of Stelo and further international expansion in 2026.
• Launch of a completely reimagined Stelo app experience with AI-enabled features in 2026.
• Continued investments across its portfolio, including AI-driven enhanced features, in 2026.
• Commitment to achieving even greater coverage to increase access to glucose biosensors for anyone with diabetes.

Key Dates

Recommendation

Dexcom has demonstrated robust financial performance, exceeding its own revenue guidance for both Q4 and the full fiscal year 2025. The company's initial 2026 outlook projects continued strong revenue growth (11-13%) and improved profitability margins, indicating sustained momentum in the rapidly expanding CGM market. The smooth transition to a new CEO, Jake Leach, who has a deep understanding of the company's technology and operations, coupled with a clear strategic vision for innovation (AI-enabled Stelo app, G7 15 Day expansion) and market penetration (international growth, expanded coverage), positions Dexcom for continued leadership and value creation. These factors collectively suggest a strong investment opportunity.

Keywords

Dexcom, DXCM, CGM, Continuous Glucose Monitoring, Financial Results, Revenue Guidance, 2026 Outlook, Jake Leach CEO, Stelo App, G7 15 Day, Biosensing Technology, Diabetes Management, Metabolic Health